This trial is active, not recruiting.

Condition multiple endocrine neoplasia
Treatment questionnaire
Sponsor M.D. Anderson Cancer Center
Start date May 2007
End date May 2018
Trial size 581 participants
Trial identifier NCT00501449, 2006-0783


The specific aims of the study include:

1. Profile the demographic, health-related, psychosocial and behavioral characteristics of adults with MEN1 or MEN2.

2. Evaluate MEN-specific distress as well as adherence to surveillance regimens among adults with MEN1 or MEN2, and identify associated with those outcomes.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective
Patients with multiple endocrine neoplasia (MEN).
questionnaire Survey
Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.

Primary Outcomes

Profile the demographic, health-related, psychosocial and behavioral characteristics of adults with MEN1 or MEN2.
time frame: 3 Years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Adults age 18 years or older, with a clinical or genetic diagnosis of MEN1 or MEN2 2. Spouse, Significant Other, or Family Member who is at least 18 years of age and who is related to an individual who is a patient at MDACC and who has been diagnosed with MEN1. 3. Ability to read and write English Exclusion Criteria: 1) Inability to be contacted via mail (i.e., no contact information on record, incorrect address)

Additional Information

Official title Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes
Principal investigator Susan Peterson, PhD
Description The proposed cross-sectional study is intended to obtain information regarding current surveillance behaviors and other psychosocial outcomes among persons affected by the multiple endocrine neoplasia (MEN) 1 or MEN2, which are inherited conditions. Study participants will include patients who have been seen previously at MDACC for evaluation of MEN1 or MEN2. Because this is the first time investigators are contacting these patients to invite them to participate in psychosocial research, the proposed study also will help determine the feasibility of conducting similar studies in the future. Investigators anticipate that data gathered from this study will enhance existing knowledge about the psychological and behavioral aspects of the MEN syndromes, and will inform future research efforts directed toward this understudied population.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by M.D. Anderson Cancer Center.